Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the completion of the sale, the chief financial officer now directly owns 26,299 shares of the company’s stock, valued at $207,236.12. This trade represents a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Zynex Trading Up 3.6 %

Shares of ZYXI stock traded up $0.28 on Friday, hitting $8.09. The stock had a trading volume of 50,575 shares, compared to its average volume of 68,037. The company’s 50 day moving average price is $8.30 and its 200-day moving average price is $8.37. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm has a market capitalization of $257.63 million, a P/E ratio of 53.93 and a beta of 0.49.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. Analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current year.

Analyst Ratings Changes

ZYXI has been the subject of a number of recent analyst reports. Royal Bank of Canada cut their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Zynex in a report on Friday, December 6th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Gladius Capital Management LP boosted its stake in shares of Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after buying an additional 1,742 shares during the period. Investment Partners Asset Management Inc. purchased a new stake in shares of Zynex in the 3rd quarter valued at approximately $96,000. Hsbc Holdings PLC acquired a new stake in shares of Zynex in the 2nd quarter valued at $113,000. Quest Partners LLC lifted its position in shares of Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Zynex by 10.4% during the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after purchasing an additional 1,846 shares in the last quarter. 29.68% of the stock is currently owned by hedge funds and other institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.